Baxter Travenol Laboratories said Hyland Therapeutics unit started first human clinical trial genetically engineered Factor VIII , clotting agent missing blood hemophiliac .
It said unlike Factor VIII concentrate currently use , genetically engineered Factor VIII would limited availability human plasma completely free blood-borne virus , including AIDS form hepatitis , Baxter said .
Baxter also said final state U.S. clinical trial highly purified form Factor VIII derived human plasma produced using advanced process incorporating monoclonal antibody purification .
It said Genetics Institute , publicly held biotechnology company Baxter shareholder , supply protein used human clinical testing , well substantial portion ongoing production requirement .
Reuter & # 3 ; 